Items Tagged ‘non-small cell lung cancer’

October 25th, 2016

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer

By

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1, such as Keytruda […]

View full entry

Tags: fda, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


June 6th, 2016

PD-1 Inhibitor Keytruda® Combined with Chemotherapy Promising in Lung Cancer Will be Evaluated in Larger Clinical Trials

By

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, new data evaluating Keytruda® (pembrolizumab) in combination with chemotherapy appears promising for the treatment of non-small cell lung cancer (NSCLC). Based on these initial results, two comparative clinical trials have been initiated. The programmed death (PD-1) inhibitor Keytruda (pembrolizumab) […]

View full entry

Tags: fda, immunotherapy, KEYNOTE-189, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, PD-1 inhibitor, pembrolizumab


March 29th, 2016

Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations

By

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1 gene. Xalkori is already approved for the treatment of patients with NSCLC that have a mutation in the anaplastic lymphoma kinase (ALK) gene. Lung cancer […]

View full entry

Tags: clinical trial, crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, ROS-1 gene, xalkori


December 24th, 2015

Alecensa ™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer

By

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa ™ (Alectinib) is indicated for advanced, metastatic, ALK-positive NSCLC in patients unresponsive to or intolerant of another ALK inhibitor, Xalkori ™ (crizotinib). The investigative agent, Alecensa, produces high anti-cancer responses […]

View full entry

Tags: Alecensa, alectinib, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc


December 3rd, 2015

Alectinib Produces High Anti-Cancer Activity in Recurrent Lung Cancer

By

The investigative agent, alectinib, produces high anti-cancer responses among patients with non-small cell lung cancer (NSCLC) that have stopped responding to Xalkori™(crizotinib). These results were recently published as a rapid online communication article in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer-related deaths in the United States. Non-small cell lung […]

View full entry

Tags: alectinib, alk, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell


November 19th, 2015

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer

By

The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the treatment of lung cancer with the epidermal growth factor receptor (EGFR) T790M mutation. The indication specifies that patients must have non-small cell lung cancer (NSCLC) that has progressed despite treatment with other approved agents that block the EGFR pathway. The diagnostic […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, osimertinib, T790M mutation, tagrisso


October 19th, 2015

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer

By

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is divided into two main groups based upon the type of cells comprising the cancer: non-squamous and squamous cell. […]

View full entry

Tags: FDA approval, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, non-squamous, nsclc, opdivo, Stages I-IIIA Lung Cancer - Non-Small Cell


September 15th, 2015

FDA Grants Alectinib Priority Review for ALK-Positive Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Priority Review for alectinib, an oral anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive, non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Xalkori™ (crizotinib).  Alectinib was previously granted Breakthrough Therapy Designation by the FDA for people with ALK-positive […]

View full entry

Tags: alectinib, ALK inhibitor, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, stage III, stage IV


September 10th, 2015

Updated Trial Results Demonstrating Benefit of Opdivo® Were Released Today at the 16th World Conference on Lung Cancer

By

Results from the CheckMate -017 and -063 clinical trials evaluating Opdivo® (nivolumab) in previously treated squamous cell non-small cell lung cancer (NSCLC) were released today at the 16th World Conference on Lung Cancer (Abstract #736), and the studies showed sustained survival benefit. Both trials showed an estimated 18-month overall survival (OS) rate of 27% (CheckMate […]

View full entry

Tags: CheckMate, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, nsclc, opdivo, PD-1 inhibitors, Recurrent Lung Cancer - Non-Small Cell, stage III, stage IV


June 25th, 2015

Aetna Provides Coverage for Biodesix’ VeriStrat Test

By

Biodesix, Inc. announced that its VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation (NYSE: AET).  Aetna published a positive coverage policy for the VeriStrat proteomic test on June 5th, stating the test is medically necessary “for patients with advanced NSCLC, whose tumors were without EGFR and anaplastic lymphoma kinase (ALK) mutations…” Aetna’s […]

View full entry

Tags: health coverage, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, proteomic blood test, Stages IIIB-IV Lung Cancer - Non-Small Cell, VeriStrat test


May 20th, 2015

Xilonix™ Promising as Treatment for Non–Small Cell Lung Cancer

By

The new targeted agent Xilonix™ appears effective in the treatment a non–small cell lung cancer (NSCLC). The biotechnology company XBoitech Inc recently announced clinical trial findings for the drug.[i],[ii] Xilonix is a type of drug known as a true human antibody. These types of drugs use antibodies that are made in the lab rather than […]

View full entry

Tags: antibody therapy, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, true human antibody, xilonix


March 16th, 2015

Zykadia™

By

Class: Biological Therapy Generic Name: ceritinib Trade Name: Zykadia™   For which conditions is this drug approved? Zykadia is approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) that is caused by a defect in a gene called ALK (anaplastic lymphoma kinase) whose disease has worsened after taking Xalkori® (crizotinib) or cannot […]

View full entry

Tags: Biological Therapy, Drug Dictionary, non-small cell lung cancer, Z


March 16th, 2015

ceritinib

By

Class: Biological Therapy Generic Name: ceritinib Trade Name: Zykadia™ For which conditions is this drug approved? Zykadia is approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) that is caused by a defect in a gene called ALK (anaplastic lymphoma kinase) whose disease has worsened after taking Xalkori® (crizotinib) or cannot tolerate […]

View full entry

Tags: Biological Therapy, C, Drug Dictionary, non-small cell lung cancer


February 26th, 2015

FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer

By

The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted for the treatment of people with PD-L1 (Programmed Death-Ligand 1) positive non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy. Lung cancer remains the leading cause of […]

View full entry

Tags: anti-PDL1, Breakthrough Therapy Designation, Lung Cancer, Lung Cancer - Non-Small Cell, MPDL3280A, News, non-small cell lung cancer, nsclc, PDL1, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


February 10th, 2015

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC

By

In a phase II trial reported in the Journal of Clinical Oncology doctors reported that the addition of linifanib to carboplatin-paclitaxel chemotherapy the outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However the addition of linifanib did result in greater side effects from treatment. Lung cancer remains the leading cause of cancer-related […]

View full entry

Tags: General Lung Cancer, linifanib, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nonsquamous, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell